DUTCH-WAIST: semaglutide and heart rhythm

DUTCH-WAIST is testing whether weight loss supported by semaglutide can improve heart-rhythm control in people with overweight or obesity and recently detected persistent atrial fibrillation. The important word is testing. The paper published on September 14, 2026 describes the trial design, not its results, so it cannot yet tell us whether semaglutide keeps more participants in normal rhythm after cardioversion^[1].

This matters because excess weight is associated with the development and progression of atrial fibrillation. Weight loss is already part of risk-factor management, but researchers still do not know which weight-management strategy produces the most useful rhythm outcome for a defined group of patients. DUTCH-WAIST is designed to test a medicine-assisted strategy rather than assume that weight loss automatically fixes the arrhythmia^[1].

What the DUTCH-WAIST trial will test

DUTCH-WAIST is a multicentre, double-blind, randomized, placebo-controlled trial in the Netherlands. It plans to compare semaglutide with placebo for one year. Both groups also receive a combined lifestyle intervention and standard atrial-fibrillation care. That design matters because it asks whether adding semaglutide changes rhythm outcomes beyond the care and lifestyle support offered to everyone in the study^[1].

Eligible participants are adults with first detected persistent atrial fibrillation of less than six months' duration who are scheduled for electrical cardioversion. They must have a body mass index above 30, or above 27 with a weight-related condition. This is a specific clinical population. The eventual findings should not be treated as evidence for people without atrial fibrillation, for every type of atrial fibrillation, or for unsupervised weight-loss treatment^[1].

Why cardioversion does not settle the problem

Electrical cardioversion uses a controlled shock to restore the heart's normal rhythm. Restoring rhythm and maintaining it are different jobs. Persistent atrial fibrillation can return after a successful procedure, and underlying factors such as excess weight may continue to influence the heart's structure and electrical behavior. DUTCH-WAIST places weight management alongside standard rhythm care because the researchers want to know whether changing that background risk improves what happens over the following year.

The trial's first co-primary outcome ranks participants by rhythm status at one year, from arrhythmic death at the most severe end to normal sinus rhythm without extra rhythm-control support at the other. Its second combines persistent atrial fibrillation on an electrocardiogram, catheter ablation, arrhythmic death, or a serious adverse event caused by an anti-arrhythmic medicine. These outcomes look beyond weight on a scale and ask whether the treatment strategy changes clinically meaningful rhythm care^[1].

What earlier research can tell us

Earlier research gives a reason for the trial, but not its answer. A 2026 randomized trial called LOSE-AF studied 118 adults aged 60 to 85 with overweight and persistent atrial fibrillation. A low-calorie diet plus behavioral support produced greater weight loss than usual care after eight months, but it did not significantly improve atrial-fibrillation symptoms, measured rhythm burden, cardiac imaging findings, or the need for further rhythm procedures^[2].

That result is a useful warning against a simple equation in which any weight loss must produce better rhythm control. It also does not answer DUTCH-WAIST. LOSE-AF tested a different intervention, used an older population, followed participants for eight months, and was not a semaglutide trial. A neutral result in one study can sharpen the need for a different trial without predicting that the next study will be positive or negative^[2].

Semaglutide has been studied in people with obesity-related heart failure with preserved ejection fraction, including participants with a history of atrial fibrillation. A pooled secondary analysis of 1,145 participants reported improved heart-failure symptoms, physical limitations, exercise function and body weight with semaglutide in people with and without atrial fibrillation. The analysis did not test maintenance of sinus rhythm after cardioversion, which is the central DUTCH-WAIST question^[3].

How to read the future result

When DUTCH-WAIST reports results, the scale of weight loss will be only one part of the story. The comparison between groups, confidence intervals, withdrawals, serious adverse events and use of additional rhythm treatment will all matter. A favorable average result would not mean that every participant remained in normal rhythm. A neutral result would not mean that weight management has no health value. It would mean that this specific strategy did not show the tested rhythm benefit under the study conditions.

Funding and competing interests will also deserve attention. The design paper reports that one author received lecture payments from Novo Nordisk, the manufacturer of semaglutide. A disclosed relationship does not invalidate a trial, but it belongs in the reader's assessment alongside randomization, blinding, outcome definitions, missing data and the final statistical analysis^[1].

What we do not yet know

We do not yet know whether adding semaglutide to lifestyle intervention and standard care improves one-year rhythm control in DUTCH-WAIST. We also do not know whether any effect would be explained mainly by weight loss, whether benefits and harms differ across subgroups, or how well the findings would transfer outside the study population. Those questions require completed follow-up and reported results, not inference from the rationale paper^[1].

People with atrial fibrillation should not change rhythm medicines, anticoagulation, cardioversion plans or weight treatment because of a trial-design paper. Those decisions need the clinician managing the condition. For evidence and current regulatory context on the medicine, see the semaglutide research page and its regulatory overview.